Dr. Craig H. Moskowitz, MD

Expert Publications

• High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
• Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: who benefits?
• Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
• Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
• Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma.
• Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999.
• Mantle cell lymphomas.
• Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation.
• Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
• Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
• CD5 negative, Cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen.
• Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma.
• High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
• Controversies in the treatment of lymphoma with autologous transplantation.

Media Releases

Get to know Hematologist-Oncologist Dr. Craig H. Moskowitz, who serves patients in Miami, Florida.

Dr. Moskowitz is an internationally recognized leader in lymphoma clinical research and treatment, specializing in the care of patients with Hodgkin lymphoma and non-Hodgkin lymphoma.

As the Physician-in-Chief of the Oncology Service Line at the University of Miami Sylvester Comprehensive Cancer Center, he is responsible for the development, implementation, and administration of high quality, value-based oncology care at the main campus and satellites. He works across departments to improve the multidisciplinary care of cancer patients. 

As the leader of the Site Disease Groups, Dr. Moskowitz collaborates with group directors to enhance the patient navigation system and fosters multidisciplinary participation in the development and piloting of clinical trials.

Teaching students, he serves as a Professor within the Department of Medicine, Division of Medicine at the University of Miami Leonard M. Miller School of Medicine.

In regards to his educational background, Dr. Moskowitz graduated with his Bachelor of Science degree from Brooklyn College in 1980. He then went on to earn his medical degree from the Wayne State University School of Medicine in 1988.

Furthering his training, he performed his residency in internal medicine at Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses) in 1992, and his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in 1995.

Licensed to practice medicine in Florida and New York, the doctor is board-certified in medical oncology by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

Practice-changing, Dr. Moskowitz’s research focuses on improving the outcomes of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma. It has led to changes in the international standard of care for lymphoma patients. 

One area of accomplishment has been to optimize high-dose therapy and autologous stem cell transplantation, as well as new agents, to improve “salvage” therapy for patients with disease that has returned or is not responding to standard therapy. His second area of accomplishment has been to develop strategies that optimize the treatment of newly diagnosed DLBCL patients, according to the likelihood of their disease recurring. These include designing risk-adapted therapies, based on risk factors present before treatment and also the results of imaging studies. 

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Having been recognized for his research on a national level through multiple awards, Dr. Moskowitz has lectured worldwide on lymphoma and stem cell transplantation. In addition, he is a member of the research council at MSKCC, and on the steering committees for the bi-annual international lymphoma conference in Lugano and the international Hodgkin lymphoma conference in Cologne.

Recommended Articles

• This Ovarian Cancer Treatment Gives Patients Freedom During Chemotherapy

  PARP inhibitors are making a big difference to cancer patients. Since they are administered orally, patients have the freedom to take them at home, and aren’t restricted by hospital visits for chemotherapy. Here’s Laurie McAndrews’s story.In December 2014, Laurie McAndrews from Illinois was...

• How Common is Testicular Cancer?

  Testicular cancer is a form of cancer which affects the male testes or sex glands encased within the scrotum, a loose sac of tissue that hangs freely below the penis. Germ cells are specialized cells lining several heavily coiled tubular structures within the testes that are responsible for...

• Holistic Treatments for Liver Cancer

  Holistic treatment for liver cancer indicates a science of healing that uses the person's whole spirit, mind and body. This treatment practice integrates the alternative and conventional therapies used to prevent and treat liver cancer, as well as promote the patient's wellbeing. The principle...

• This 12-year-old Is an Anomaly in the Ovarian Cancer Community

  Ovarian cancer usually strikes women who are at least in their fifties; however, Olivia Parslow is only twelve years old and is fighting the disease with her life.Olivia's storyOlivia had gained nearly 40 pounds in only three weeks, so her family was very concerned. Not only was she gaining an...

• Alternative Treatments for Bladder Cancer

  Alternative Treatments for Bladder CancerCancer occurs in various stages, and as it moves from one stage to another, it gets worse. Therefore, as the condition progresses, more effective methods of treatment have to be applied. At times, even two treatment methods can be applied together.In...

• Jackie Kennedy Onassis's Battle with Lymphoma

  Jackie Kennedy Onassis is one of the most iconic first ladies of all time, and an important cultural icon of the 20th century. Not only did she establish a model for the behavior and protocol of the first ladies that would follow her, but she was also a fashion icon and a well-respected book editor...